EUVIMEDEUVIMED entdecken
Crossref

A Novel Topical Compound Gel Loading Minoxidil and Tofacitinib for Treatment of Alopecia Areata: Formulation, Characterization, and In Vitro/In Vivo Evaluation

Rui Wang, Ying Zhou, Peng Yang, Hailong Zhang, Jinsong Ding iD

Drug Development Research · 2025

DOI: 10.1002/ddr.70076 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Development Research, 2025. Verfasst von Rui Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, Hunan, China. Hauptthemen laut MEDLINE: Alopecia Areata, Minoxidil, Pyrimidines, Piperidines. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: This work was supported by Changsha Jingyi Pharmaceutical Technology Co. Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Although topical minoxidil is the most common drug for alopecia areata (AA), it has limited therapeutic effect in the treatment of patients with moderate and severe AA because it can only promote hair follicle growth and improve the characteristics of hair follicle degeneration in AA and cannot alleviate local inflammatory response. Therefore, we designed a novel topical compound gel loading minoxidil and Janus kinases (JAK) inhibitors tofacitinib. The compound gel not only had good semi‐solid properties and the effect of permeation but also maintained stability for up to 3 months under accelerated conditions, ensuring the long‐term quality of the formulation. This compound gel can effectively improve hair follicle growth and significantly alleviate local inflammatory response by downregulation of the ratio of inflammatory factor interferon‐γ to anti‐inflammatory factor interleukin‐4 in C3H/HeN mice bearing AA, achieving the purpose of synergistic treatment of AA. The first combination of minoxidil and tofacitinib in a topical formulation gives a new idea for the clinical treatment of AA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alopecia AreataMinoxidilPyrimidinesPiperidinesPyrrolesAnimalsGelsMiceMice, Inbred C3HHair FollicleAdministration, TopicalMaleJanus Kinase Inhibitors

Stichwörter der Autor:innen

JAK inhibitors‐tofacitinibalopecia areataminoxidiltopical compound gel

Substanzen

tofacitinibMinoxidilPyrimidinesPiperidinesGelsPyrrolesJanus Kinase Inhibitors

Autor:innen und Institutionen

  • Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, Hunan, China.
  • School of Life Science and Technology, Harbin Institute of Technology, Harbin, Heilongjiang, China.
  • Changsha Jingyi Pharmaceutical Technology Co. Ltd., Changsha, Hunan, China.
  • Hunan Engineering Research Center of Transdermal Drug Delivery Systems, Changsha, Hunan, China.

ORCID-Profile: Jinsong Ding

Förderung

  • This work was supported by Changsha Jingyi Pharmaceutical Technology Co. Ltd.

Zitieren

APA

Wang, R., Zhou, Y., Yang, P., Zhang, H., & Ding, J. (2025). A Novel Topical Compound Gel Loading Minoxidil and Tofacitinib for Treatment of Alopecia Areata: Formulation, Characterization, and In Vitro/In Vivo Evaluation. Drug Development Research. https://doi.org/10.1002/ddr.70076

Vancouver

Wang R, Zhou Y, Yang P, Zhang H, Ding J. A Novel Topical Compound Gel Loading Minoxidil and Tofacitinib for Treatment of Alopecia Areata: Formulation, Characterization, and In Vitro/In Vivo Evaluation. Drug Development Research. 2025. doi:10.1002/ddr.70076

BibTeX
@article{Wang2025,
  author = {Wang, Rui and Zhou, Ying and Yang, Peng and Zhang, Hailong and Ding, Jinsong},
  title = {A Novel Topical Compound Gel Loading Minoxidil and Tofacitinib for Treatment of Alopecia Areata: Formulation, Characterization, and In Vitro/In Vivo Evaluation},
  journal = {Drug Development Research},
  year = {2025},
  doi = {10.1002/ddr.70076}
}
Kostenlos starten →